Extensive research into the molecular mechanisms of cancer disease has heralded a new age of targeted therapy. In malignant cells, key proteins that are crucial to tumor growth and survival are now being targeted directly with rationally designed inhibitors. Apart from monoclonal antibodies, small molecule therapeutics such as oncogenic protein kinase inhibitors are attracting a vast amount of investigational attention. This textbook, written by acknowledged experts, provides a broad overview of the small molecules currently used for the treatment of malignant diseases and discusses interesting novel compounds that are in the process of clinical development to combat cancer.
Author(s): Cornelius F. Waller (auth.), Uwe M. Martens (eds.)
Series: Recent Results in Cancer Research 184
Edition: 1st Edition.
Publisher: Springer Berlin Heidelberg
Year: 2010
Language: English
Pages: 254
Tags: Oncology; Hematology; Cancer Research
Front Matter....Pages i-xvi
Front Matter....Pages 1-1
Imatinib Mesylate....Pages 3-20
Erlotinib....Pages 21-31
Axitinib (AG-013736)....Pages 33-44
Lapatinib....Pages 45-59
Sorafenib....Pages 61-70
Sunitinib....Pages 71-82
Dasatinib....Pages 83-102
Nilotinib....Pages 103-117
Bosutinib....Pages 119-127
Front Matter....Pages 130-130
Decitabine....Pages 131-157
5-Azacytidine/Azacitidine....Pages 159-170
Front Matter....Pages 172-172
Bortezomib....Pages 173-187
Temsirolimus....Pages 189-197
Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor....Pages 199-214
BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)....Pages 215-218
Front Matter....Pages 220-220
Imetelstat (GRN163L) - Telomerase-Based Cancer Therapy....Pages 221-234
GDC-0449 - Targeting the Hedgehog Signaling Pathway....Pages 235-238
